Genomic Biomarker-Driven Treatment Strategy in PTCL
Abstract
Peripheral T-cell lymphomas (PTCL) are a heterogeneous, difficult-to-diagnose group of cancers that constitute up to approximately 10%-20% of all non-Hodgkin’s lymphomas and are associated with a poor prognosis. PTCL patients more often relapse, and no real effective therapy has been developed for these patients. Consequently, no improvement in overall survival over the past 2 decades was observed. However, novel therapies with targeted agents to specific subtypes of PTCL have recently begun to be tested, some with remarkable results. We have identified a specific subset of genes that can differentiate PTCLs entities with high precision and aid in putting patients into important prognostication groups. This scientific proposal describes the development of a novel clinical diagnostic test for use in the clinics and effective treatments for each patient and ultimately, improving the outcomes of individuals with these cancers. With this research we propose to use DNA/RNA from tissue biopsies and corresponding circulating tumor DNA in blood plasma of the PTCL for accurate diagnosis and disease monitoring. We will apply highly sensitive and novel molecular assays for tumor characterizing using RNA and DNA detect mutant tumor DNA in blood that are collected as part of ongoing clinical trials using a multi-drug regimen in patients with recurrent PTCL. We aim to increase diagnostic and prognostic accuracy using RNA and DNA-based assays and obviate the need for repeated biopsies, facilitate personalized therapy, and improve patient outcomes using this liquid biopsy approach. These studies will meaningfully advance the standard-of-care for treatment of PTCL subtypes in the relapsed/refractory setting within the next 3 years, while informing trials to improve cure rates in the upfront setting. In summary, this proposal builds on hypotheses supported by extensive genomic analysis of PTCLs to enhance the precision in diagnosis as well as the application of precision therapeutic approaches.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Dec 28, 2022
- Source ID
- W81XWH2210396
Entities
People
- Javeed Iqbal
Organizations
- United States Army
- University of Nebraska Medical Center